Fig. 4

PTX3 affects TNBC cell growth in vivo. (A) Tumor growth and representative pictures (left panel) and weight (right panel) of control (shNT) and PTX3-silenced (shPTX3) MDA-MB-231 orthotopic tumors grown in immune-compromised mice. (B) Immunohistochemical analysis (left panel) of MDA-MB-231 shNT and shPTX3 tumors and quantification (right panel) of pHH3⁺ cells and CD44⁺ area by ImageJ analysis. Scale bar: 50 μm. (C) Tumor growth, weight and representative pictures of control (mock) and PTX3-overexpressing (PTX3) MDA-MB 468 orthotopic tumors grown in immune-compromised mice, and (D) of PTX3-overexpressing (PTX3) E0771 orthotopic tumors grown in immune competent syngeneic mice. In box and whiskers graphs, boxes extend from the 25th to the 75th percentiles, lines indicate the median values, and whiskers indicate the range of values. n = 8/10 mice/group; *p < 0.05, **p < 0.01, ***p < 0.001